Streetbeat News

Products Services

RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has initiated dosing in the second cohort of its Phase 1/2/3 Cyprus2+ trial for UX701 gene therapy, aimed at treating Wilson disease. The first dose cohort was well tolerated with no unexpected adverse events. The company is on track to complete enrollment in Stage 1 of the trial this year and expects to share initial data in the first half of 2024.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:09 pm

DARE

Daré Bioscience, Inc. (NASDAQ:DARE) has been awarded a grant of approximately $385,000 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH). The grant will support the development of a potential new therapeutic intervention for the prevention and treatment of idiopathic preterm birth. Daré will collaborate with the Lockwood Laboratory at the University of South Florida (USF) Morsani College of Medicine on the grant-funded activities.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:09 pm

AYTU

Aytu BioPharma has signed an exclusive agreement with Medomie Pharma to commercialize its ADHD treatment tablets, Adzenys XR-ODT and Cotempla XR-ODT, in Israel and the Palestinian Authority. This is Aytu's first international commercial agreement for these products. Medomie will seek local regulatory approvals and marketing authorizations for both products.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:06 pm

ENLV

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) has announced the dosing of the first patient under the amended protocol for its Phase II trial of Allocetra in patients with sepsis. The amended protocol allows for a higher SOFA score inclusion range, enabling the recruitment of patients with higher levels of sepsis severity. The company expects the top-line data readout from the Phase II trial in Q1 2024.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:05 pm

LDOS

MSFT

Leidos and Microsoft have announced a collaboration to expedite the development of advanced cloud technology. The partnership aims to leverage Microsoft's Azure platform and Leidos' expertise in digital modernization to deliver innovative solutions.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:05 pm

TSHA

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a recommendation from the Independent Data Monitoring Committee (IDMC) to continue the REVEAL Phase 1/2 trial for Rett syndrome. The decision was based on encouraging initial clinical data from the first patient dosed with TSHA-102. The dosing of the second patient is expected in Q3 2023. TSHA-102 is an investigational gene therapy for Rett syndrome, a rare genetic neurodevelopmental disorder.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:05 pm

ATNF

180 Life Sciences Corp. (NASDAQ:ATNF) has filed a provisional patent for the combination of CBD and GLP-1 agonists for obesity and weight management. The company believes that the combination of these two compounds could stimulate a common therapeutic pathway. The company is currently in negotiations with third-party scientists for a research collaboration to test this theory. If successful, this could lead to human clinical trials.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:04 pm

QTRX

Quanterix's Simoa technology has been used in a large international reference range study to assess neurological disease activity in pediatric patients using serum neurofilament light. The study could potentially lead to significant advancements in the field of pediatric neurology.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:03 pm

SXTP

60 Degrees Pharmaceuticals has been awarded a Canadian patent for Tafenoquine, a drug used for the prevention of malaria in malaria-naive subjects.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:01 pm

JBHT

NKLA

J.B. Hunt Transport Services Inc. (NASDAQ:JBHT) has agreed to purchase 13 zero-emission Class 8 trucks from Nikola Corporation (NASDAQ:NKLA). This move is part of J.B. Hunt's sustainability efforts and aims to reduce its carbon emissions.

Portfolio Pulse from Charles Gross

July 31, 2023 | 11:52 am